• Alberta’s cannabis industry regulatory agency has lifted a moratorium on accepting new retail licenses
• Budd Hutt is seeking retail partnerships in Alberta and across Canada
• CVGR CEO indicated that the lifting of the moratorium motivates the company to complete its buildout of a cannabis production facility

City View Green Holdings Inc. (CSE: CVGR) is poised to benefit following Alberta’s AGLC regulatory agency’s decision to lift its moratorium on accepting new retail cannabis licenses, announcing that it will issue five new licenses weekly (http://ibn.fm/dRNM1). CVGR sees the move as providing a direct route to market for its products, as Budd Hutt, the company’s retail arm, seeks strong financial investment partners and retail partnerships in Alberta and across Canada (http://ibn.fm/jR11d). CVGR CEO Ian MacDonald said that the move would add value to the company’s 19.9 percent equity position in Budd Hutt and, ultimately, its shareholders.

For retail-focused cannabis company Budd Hutt, the addition of brick-and-mortar retail stores would cement the brand and the company in the recreational cannabis market while it prepares for growth into Ontario and other key markets in the near future.

The company expects to announce a retail partnership prior to the end of Q3 2019. Budd Hutt CEO Craig Belcher said in a news release that the company is “laser focused on acquiring the right retail opportunities in the right locations that will showcase Budd Hutt’s outstanding design and concept and provide consumers with a best-in-class experience in and out of (its) retail locations.”

“The lifting of the licensing moratorium in Alberta is extremely exciting and further motivates CVG towards completing our buildout of our Brantford facility and obtaining our licensing so we can ensure we supply Budd Hutt with unique products of the highest quality and consistency,” MacDonald stated in a news release.

Toronto, Canada-based CVGR is a vertically integrated, seed-to-sale cannabis company that’s planning to grow high-quality cannabis and produce extracts. The company anticipates producing edible products, distillates and water-soluble products for the beverage market once they become legalized. CVGR is focused on becoming a diversified company that will potentially acquire targets in the cannabis industry.

For more information, visit the company’s website at www.CityViewGreen.ca

NOTE TO INVESTORS: The latest news and updates relating to CVGR are available in the company’s newsroom at http://ibn.fm/CVGR

• Canada-based Willow Biosciences and U.S.-based Noramco are teaming to biosynthetically produce and market pharmaceutical-grade cannabidiol (CBD)
• The companies expect to deliver yeast-cultivated CBD as a low-cost, ultra-pure alternative to cannabis cultivation that avoids large-scale plant waste from greenhouse processes
• Yeast-grown pharmaceutical ingredients have long served as fodder for insulin and other important drugs; the growing interest in cannabis as a therapy is driving a booming new market

The sea change in societal attitudes about cannabis, accompanied by the opening of governmental regulatory doors for its use (http://ibn.fm/KDlfq), has spawned a land rush by corporate interests set on staking out market territory for business development (http://ibn.fm/8HLQS). The so-called “green rush” began when chronically ill patients reported that cannabis properties provided accessible relief for select conditions. Now, InvestmentPitch Media is reporting in a new video that cannabis industry newcomer Willow Biosciences Inc. (CSE: WLLW) can deliver high yields of ultra-pure, low-cost cannabinoids to an evolving market utilizing proprietary biosynthetic processes.

The video (http://ibn.fm/gRZL3) highlights a recent joint development agreement between Alberta, Canada-based Willow Biosciences and Delaware-headquartered Noramco that will build on Willow’s experience in developing manufacturing processes for active pharmaceutical ingredients (APIs) that treat conditions such as cancer, pain and central nervous system disorders, as well as Noramco’s experience in producing high-quality synthetic cannabinoid APIs for the pharmaceutical and health care industry.

Under the agreement, Willow will focus on developing ultra-pure CBD with its pioneering biosynthetic technology, bypassing the costs and waste associated with plant cultivation for a single cannabinoid by optimizing yeast cultivation processes, while Noramco will be responsible for the scale-up, regulatory applications, marketing and distribution of the companies’ products. Their work has the potential to open new and larger markets for CBD and related compounds, as well as providing low-cost solutions to pharmaceutical partners.

“Biosynthesis, in yeast in particular and other processes, is used for producing insulin (and) artemisinin… There are numerous drugs, for example, that are in production today because of biosynthesis,” Willow CEO Trevor Peters said during a May 24 interview with Midas Letter (http://ibn.fm/rvgSE).

“We look at the cannabinoids as an ingredient as opposed to a cultivation process,” Peters added. “It’s baker’s yeast, essentially, that we use. It’s no different than brewing beer, with slightly more complicated – well, much more complicated science that’s involved in actually developing the yeast strain… I’m not sure what the biomass equivalents would be in a greenhouse, but I’m sure you’d be talking about hundreds of thousands of square feet to come up with the same product over a three- to four-month period.”

Noramco Chief Innovation Officer Bill Grubb, the vice president of global business development, expressed his confidence in Willow’s ability to deliver scalable CBD strains through the InvestmentPitch video report.

“The addition of biosynthetic CBD production will augment Noramco’s ability to work with our existing customers and (give Noramco) the capacity to address the rapidly increasing market demand for CBD-based APIs and ingredients from pharmaceutical, nutraceutical, consumer packaged goods, beverage and other industry sectors,” Grubb stated.

For more information, visit the company’s website at www.WillowBio.com

NOTE TO INVESTORS: The latest news and updates relating to WLLW are available in the company’s newsroom at http://ibn.fm/WLLW

• Geyser Brands is a cannabis consumer wellness company dedicated to helping people look, feel and do their best
• The company announced June 18 that wholly owned subsidiary Apothecary Botanicals has been awarded a processing license, allowing GYSR to advance its brands
• Geyser’s LOI to acquire Solace Management Group is expected to give the company additional wellness brands for humans and their pets, once due diligence is completed

Consumer wellness brand cultivator Geyser Brands Inc. (TSX.V: GYSR) is moving forward with its vision of developing premier cannabis-enhanced products following Health Canada’s announcement that the company’s wholly owned subsidiary, Apothecary Botanicals (0957102 B.C. Ltd.), has been awarded a coveted standard processing license.

“This is a huge milestone for Geyser Brands and something that we have been working towards for many months,” CEO Andreas Thatcher stated in a news release announcing Health Canada’s decision (http://ibn.fm/97gi1). “The license allows us to add value to existing consumer health care brands by providing them the platform to add CBD. It also reflects our business model to focus our Licensed Producer on delivering scale through manufacturing and distribution.”

Geyser Brands is a British Columbia-based company whose products leverage a proprietary NanoFusion technology to make bioavailable formulations for promoting human and pet health. In March, the company celebrated its first successful harvest of hemp test crops under the requirements of Health Canada’s license to cultivate cannabis, and, in May, GYSR began operations at its Apothecary Botanicals manufacturing facility.

Physical modifications to the facility to deliver GMP-compliant capacity are complete, according to the announcement, and Geyser expects to begin production of in-house formulated products for future branding of edibles, extracts and topicals at the facility within the next 30 days.

The new license allows Geyser to begin work to extend its cannabidiol products to the regulated Canadian consumer medical market as the company awaits its sales license. The company’s nano-emulsion technology carries oil and hemp terpene-infused benefits quickly and efficiently into the bloodstream for rapid relief of pain while boosting the body’s general abilities with all-natural ingredients.

In keeping with its mission to develop CBD products for the wellness market, Geyser is working to complete its due diligence following an LOI to acquire Solace Management Group Inc.’s brands and assets, which include hemp-based product line Apothecary Naturals, hemp-based tattoo after-care products Apothecary Ink, hemp oil pet treats under the Apawthecary Pets brand and WildTail Pets freeze-dried food products for dogs and cats.

Solace distributes the branded products to thousands of stores in Canada, Europe, the Caribbean and North America. The acquisition is subject to the necessary approvals from the respective boards, shareholders and TSX Venture Exchange.

The changes to the Apothecary Botanicals facility will also include a laboratory for research and development. With the modifications complete, the company anticipates receiving its R&D and sales licenses in the coming months.

For more information, visit the company’s website at www.GeyserBrands.com

NOTE TO INVESTORS: The latest news and updates relating to GYSR are available in the company’s newsroom at http://ibn.fm/GYSR

• Wildflower Brands has completed a distribution deal that places its CBD-based SKUs at nearly 300 Dillard’s stores nationwide
• Wildflower’s products are also being sold through bohemian lifestyle outlet Free People, which is labeling the products as part of its Beauty and Wellness Collection
• Wildflower’s success has led to the hiring of a second shift of employees at its Washington production facility and the start of construction of a new facility to keep pace with demand

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) is getting its cannabis-based wellness products into an expanding number of consumers’ hands through retail partnerships that are not only extending the wholesome lifestyle brand’s reach but its mainstream market exposure as well.

Wildflower announced June 17 (http://ibn.fm/QeiOy) that the company has received and fulfilled an opening purchase order from Dillard’s department stores that will give Wildflower’s premium hemp SKUs a presence in 292 Dillard’s stores nationwide. The deal is particularly attractive, because it gives Wildflower an access channel in the large markets of Florida and Texas.

“Launching into Dillard’s will double the number of retail locations we are in overnight,” Wildflower CEO William Maclean stated in a news release. “Our strategy is to build off our established brand equity in these key markets that can catapult us into becoming a household name. Dillard’s has the respect and reputation as a retailer that fits in with our loyal following.”

The company also announced June 11 that cannabidiol (CBD) products including Wildflower CBD+ Cool Stick, Wildflower CBD+ Healing Stick, Wildflower CBD+ Vanilla Soap and Wildflower CBD+ Lavender Soap are being sold through bohemian lifestyle brand Free People’s website (http://ibn.fm/nFfMo), further extending Wildflower’s exposure.

The products are available under Free People’s Beauty and Wellness Collection, promising cruelty-free, mostly natural and organic remedies for physical discomforts and the deleterious skin effects of aging.

Thanks to Wildflower’s success at forging retail partnerships, the company finds itself faced with a demand to build a new production facility that can better keep pace with the increasing call from consumers for the CBD-wellness products.

The new facility is expected to be completed in August and to fully automate production of its SKUs. In the meantime, Wildflower has added a second shift at its existing Bellingham, Washington, production facility to keep pace with demand, which still leaves production at 90 percent of capacity, according to the company (http://ibn.fm/crrgq).

“We receive inbound contact daily by new retailers and distributors reaching out to us to carry our products and with production at near capacity we need the expanded manufacturing,” Maclean added.

Completion of the new facility is expected to increase Wildflower’s production capacity by more than tenfold.

Wildflower holds 14 licenses for cannabis cultivation, manufacturing, distribution and retail in California, the world’s largest cannabis market. The company’s distribution network extends beyond California to encompass more than 200 retailers in Washington and more than 20 in New York City, with additional distribution throughout the country. The inclusion of Dillard’s stores means that Wildflower products are in distribution in roughly 600 locations across America.

For more information, visit the company’s website at www.WildflowerBrands.co

NOTE TO INVESTORS: The latest news and updates relating to WLDFF are available in the company’s newsroom at http://ibn.fm/WLDFF

• Earth Science Tech markets high quality, full-spectrum hemp CBD oil
• The company’s subsidiaries focus on developing roles as international leaders in the CBD arena
• ETST has various partnerships in place to foster product innovation

Earth Science Tech Inc. (OTCQB: ETST) operates in the fields of hemp cannabinoids, nutraceuticals, pharmaceuticals, medical devices and research and development. Headquartered in Doral, Florida, the company offers CBD in the form of vitamins, minerals, herbs, botanicals, personal-care products, homeopathies, functional foods and other products. An inventive biotech enterprise, ETST provides high purity and quality full-spectrum hemp CBD oil to the booming CBD market.

The company’s wholly owned subsidiaries focus on developing ETST’s role as a global leader in the CBD space. The subsidiaries also focus on expanding Earth Science Tech’s work in the pharmaceutical and medical device sectors. Earth Science Tech’s business approach includes promoting its varied portfolio and pipeline while also engaging in strategic partnerships.

ETST has partnered with the University of Central Oklahoma and DV Biologics Laboratory to work on projects that scientifically support and advance the health care benefits of its high-grade hemp CBD oil. Earth Science Tech’s CBD oil is 100 percent natural and organic and is manufactured using a supercritical CO2 liquid extraction process.

Earth Science Tech has agreements with CannaBiz and Desert Sun Distribution (http://ibn.fm/zHKJJ). These agreements are part of a wider strategy implemented by ETST Chief Sales Officer David Burbash, who is expanding the sales team to explore product placement in large chains, health food stores and other establishments. These agreements are for the distribution of a high-grade, full-spectrum cannabinoids line throughout pharmacies, chiropractors, dispensaries, athletic clubs and clinics in the United States.

“We see tremendous synergy between our CBD line and the health care practitioner and pharmacy spaces,” Burbash stated in a news release. “The distribution agreements with CannaBiz and Desert Sun Distribution, while important, are only a fraction of the opportunities we see for our CBD products.”

ETST’s Earth Science Pharmaceutical Inc. subsidiary is developing and pioneering medical devices and vaccines to improve women’s health around the world (http://ibn.fm/OUM9x). The company is developing low-cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases (STIs). Its first medical device is MSN-2, a home kit designed for the detection of STIs such as chlamydia from a self-obtained gynecological specimen. The company is advancing clinical trials of MSN-2 via a collaborative agreement with Laboratories BNK Canada.

The company’s Cannabis Therapeutics Inc. subsidiary is a biotech firm focusing on CBD research and development for an extensive line of cannabinoid-based pharmaceuticals, nutraceuticals and other products and solutions (http://ibn.fm/26k3p). The company is working to explore and harness the medicinal power of cannabidiol. Cannabis Therapeutics has a provisional application patent for CBD, and its first projects are centered on developing treatments for breast and ovarian cancers.

Earth Science Tech also has its Canna Inno Laboratories Inc. subsidiary. The acquisition of Canna Inno provides the company with access to Government of Canada funding, the first of which has received approval (http://ibn.fm/wkHh2). Headquartered in Montreal, Canna Inno Laboratories gives Earth Science Tech a presence in the province of Quebec.

Earth Science Tech continues to advance its product development in varied dynamic sectors. The company offers investors the potential for return on investment through its CBD products and international provisional patent applications. Earth Science Tech is also advancing its vision by exploring opportunities in new medical frontiers with the unique integration of CBD with generic drug molecules.

For more information, visit the company’s website at www.EarthScienceTech.com

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at http://ibn.fm/ETST

• SHRG is entering the Canadian direct-selling market as part of its international growth strategy
• SHRG notes that the female demographic of independent salespeople in Canada aligns with its own consultants
• The company is pursuing uplisting to the Nasdaq Capital Market as a ‘natural progression’ for the company and its shareholders

Sharing Services Global Corporation (OTCQB: SHRG) is focusing on international expansion, initially by growing into the Canadian direct-selling market, which was estimated at $2.6 billion in 2017 by the Direct Sellers Association of Canada (DSA) and at $3 billion in 2019 by Ibis World (http://ibn.fm/RglFU). SHRG is also proceeding with its application for uplisting to the Nasdaq Capital Market (http://ibn.fm/Jb6WI).

SHRG has been successful in focusing its Blue Ocean Strategy on direct selling in the United States. “Our March revenues are proof that our Blue Ocean Strategy is being well accepted in the direct-selling marketplace, and we want this growth to continue within new markets,” SHRG CEO John ‘JT’ Thatch stated in a news release (http://ibn.fm/WlBXD). SHRG is embarking on expansion into Canada and other international markets (http://ibn.fm/XcX0P).

In addition, SHRG’s CEO said that DSA statistics showed that, of the 1.3 million independent sales consultants in Canada, 82 percent were women (http://ibn.fm/snMr2). That percentage dovetails with the demographics of SHRG’s marketing force of Elepreneurs independent salespeople.

For March 2019, SHRG reported record U.S. sales of $10.4 million (http://ibn.fm/y51Is). Thatch credited both SHRG’s Elepreneur LLC subsidiary’s independent sales associates and Elevacity Global LLC with that growth.

SHRG is also continuing to pursue uplisting. “A listing on the Nasdaq Capital Market is a natural progression for the company and our shareholders,” Thatch added.

SHRG is a Plano, Texas-based, diversified holdings company that owns, operates or controls a variety of companies engaged in direct selling through independent sales representatives. The company also offers services such as energy, technology and insurance. Its divisions include Elevacity Global LLC and Elepreneur LLC.

For more information, visit the company’s website at www.SHRGInc.com

NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• Petroteq Energy has been developing a proprietary clean surface oil extraction technology that it expects to revolutionize the fuel industry
• Petroteq recently announced that Texas-based energy engineering services company Valkor has contracted Petroteq’s technology for its extraction plants, paying Petroteq associated royalties
• Petroteq expects the licensing of its technology to become a significant part of its business model

Petroteq Energy Inc. (TSX.V: PQE) (OTC: PQEFF) is demonstrating the true potential value of the Clean Oil Recovery Technology (CORT) that it has developed for surface tar sands oil extraction in Utah’s rural eastern desert. The company announced July 2 that it has entered into a non-exclusive technology licensing agreement with eastern Texas energy services company Valkor LLC, marking the first in what Petroteq hopes will become a series of licensing agreements for its technology (http://ibn.fm/h70ah).

Since last year, Petroteq has been putting its technology to work at the Utah site it leases, aptly named Asphalt Ridge because of the surface bituminous resource located there. The company has been using its CORT, which is a closed-loop system that extracts fuel oils from the ground and returns the sands “cleaned” to the earth.

Valkor’s agreement to license CORT grants Valkor the non-exclusive right to use Petroteq’s patented technology to engineer, construct, operate and finance oil sands extraction from mining operations to heavy crude at Valkor’s bases of operation.

Petroteq, in return, gains a non-refundable license fee of $2 million per extraction plant and a five percent royalty based on Valkor’s annual gross sales, excluding solvent and water, for so long as the technology is covered by a valid claim in the country in which it is used. Valkor also stipulates that it will invest (or secure investment of) at least $20 million for building a plant by December 2020 and will have in production a minimum of 1,000 barrels per day.

“The licensing model is an important component of the Petroteq business model allowing Petroteq to leverage its proprietary technologies and operating techniques to participate in value created through investment by other companies and strategic investors,” the company’s announcement states.

“In working with Petroteq for the past year at its Asphalt Ridge facility in Utah, it is clear that the Petroteq technology is unique and highly effective. It fits our long-term strategy extremely well,” Valkor CEO Steve Byle noted in the news release.

For more information, visit the company’s website at www.Petroteq.energy

NOTE TO INVESTORS: The latest news and updates relating to PQEFF are available in the company’s newsroom at http://ibn.fm/PQEFF

• Proprietary bioelectronic devices developed by Endonovo Therapeutics target patient pain and inflammation while aiding wound recovery
• SofPulse® safely decreases pain by reducing edema (swelling), which decreases the need for prescription pain medications
• Endonovo’s wearable device can be used to address an array of medical conditions and is FDA-cleared for treating post-operative pain and edema in soft tissue

Endonovo Therapeutics Inc. (OTCQB: ENDV) is transforming the field of medicine by developing safe, wearable, non-invasive bioelectric medical devices that deliver Endonovo’s Electroceutical™ Therapy. Targeting inflammatory conditions in vital organs and peripheral tissues, Endonovo’s SofPulse® is clinically proven to significantly speed the recovery process and reduce the need for potentially addictive pain medications, thereby improving the patient’s natural recovery experience (http://ibn.fm/qHmMQ).

The efficacy of SofPulse targeted pulsed electromagnetic field therapy (tPEMF), which uses targeted microcurrents to transmit gentle pulses to the tissue, is well documented and supported by peer-reviewed clinical research. Among the clinical findings for patients using tPEMF are decreases in post-surgery pain, a 2.2-fold reduction in the use of narcotics, vastly improved chronic wound healing and significant reductions in inflammation and edema (http://ibn.fm/2uABB).

Endonovo recently announced a national rollout of its SofPulse post-operative opioid alternative tPEMF therapy device to hospitals, skilled nursing centers, wound care centers and pain management clinics throughout the U.S. According to the company’s news release, Endonovo plans to be in the evaluation stage with 600 hospitals within the next 18 months, employing roughly 300 sales representatives (http://ibn.fm/O9IB8). Endonovo has also entered into an agreement to distribute its SofPulse therapy device to Veterans Administration facilities and Department of Defense health care facilities (http://ibn.fm/R2cGe).

“We believe, based on numerous meetings with doctors and hospital administrators, the level of acceptance of our SofPulse device supports our plans to be in hospitals throughout all 50 states by 2020,” Alan Collier, Endonovo’s chief executive officer, said in the release. “With the public demanding change and options other than opioids, and with very few alternatives to satisfy those demands, SofPulse is a natural and safe replacement to opioids and a solution to this health crisis.”

In 2017, the U.S. Department of Health and Human Services declared a public emergency and announced a five-point strategy to combat the nationwide opioid crisis that includes advancing better practices for pain management (http://ibn.fm/fFBRg). Opioid overdoses accounted for more than 42,000 deaths in 2016, more than any previous year on record, with an estimated 40 percent of opioid overdose deaths involving a prescription opioid.

Endonovo’s Electroceutical Therapy is cleared by the U.S. Federal Drug Administration (FDA) for the palliative treatment of post-surgical pain and edema and is CE-marked in the European Economic Area for the promotion of wound healing and the palliative treatment of post-surgical pain and edema. The Centers for Medicare and Medicaid Services also has national coverage determination for the reimbursement of Electroceutical Therapy for the treatment of chronic wounds.

For more information, visit the company’s website at www.Endonovo.com

NOTE TO INVESTORS: The latest news and updates relating to ENDV are available in the company’s newsroom at http://ibn.fm/ENDV

• Trxade hosts a S2P (supplier to pharmacy) pharmaceuticals trading platform
• Over 10,500 registered pharmacies are listed on Trxade’s platform
• The company achieved record first quarter 2019 financial results driven by an increase in revenues

The proprietors of America’s independent pharmacies may well be cheering as the S2P (supplier to pharmacy) trading platform pioneered by Trxade Group Inc. (OTCQB: TRXD) swings into full gear, for its benefits extend to both trade and customers. The web-based platform not only identifies the best available prices for prescription drugs – a boon to patients – but helps pharmacists avoid negative reimbursement costs, which reduce profit margins. Over 10,500 pharmacies have already registered, and Trxade Group is hoping to convince most, if not all of the 24,000 independent pharmacies that its platform is a better deal when working with traditionally standalone group purchasing organizations (GPO) for secondary sourcing of prescription medication. The message appears to be getting a hearing. The company recently announced record first quarter 2019 financial results driven by an increase in revenues.

In the vast economic sector that is the U.S. pharmaceutical industry – $330+ billion a year – proprietors of independent pharmacies, many of whom are constrained in terms of time and resources, run $3.5 million-per-annum operations while struggling to maintain margins. In the past, they have turned to GPOs and other sourcing programs to reduce the purchase cost of drugs, which the GPOs were supposed to accomplish through the consolidation of buying power. The proof of the pudding, however, is in the eating. Over the past decade, independent pharmacies have been experiencing declining margins due to rising fees and reduced reimbursements from pharmacy benefit managers (PBMs) and volatility in drug costs.

It appears that GPOs have not been able to provide the service needed to these pharmacies. Instead, the PBMs are winning at their expense. Indeed, one study (http://ibn.fm/6lwbh) reported, “Pharmaceutical benefit managers, a once obscure segment of the health care financing landscape, have become industrial behemoths in the U.S. health sector. In 2017, the top PBMs had revenues that exceeded those of the top pharmaceutical manufacturers, for example, Express Scripts reported revenue of $100 billion while Pfizer had revenues of $52 billion.”

Express Scripts is one of three large PBMs, along with CVS Health and OptumRx, that control 78 percent of the market, with 180 million enrollees on their books.

However, the online marketplace hosted by Trxade Group offers pharmacies a real opportunity to reduce purchase costs and much more. The integrated pharmaceutical services company offers not just a web-based purchasing platform for transactions between independent pharmacists and drug distributors (B2B), but also a network of associated pharmacies with its e-hub software; a mail order pharmacy; a warehouse; and drug delivery services. Called the TRxADE Exchange, the platform gives small pharmacies access to the wider pharmaceutical distribution supply chain network, allowing them to search for and view products from manufacturers, buying groups and wholesalers on a real-time and continuous basis.

Other services offered by Trxade Group include RX Guru, an industry-leading price prediction model that integrates product shortage insight into pharmacy acquisition benchmarks. The model aims to ascertain trends and pricing variances that provide significant purchasing opportunities that are not discernible to the rest of the industry.

For more information, visit the company’s website at www.TrxadeGroup.com

NOTE TO INVESTORS: The latest news and updates relating to TRXD are available in the company’s newsroom at http://ibn.fm/TRXD

• Lexaria developed and out-licenses DehydraTECH to create new (and improve existing) drug-delivery products
• The company is credited with leading the way forward in discovering new ways to effectively deliver CBD into the human body
• Lexaria is helping firms meet supply and demand requirements by creating products that offer lower dosing with higher absorption

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is known for its innovative delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. The company developed drug-delivery platform DehydraTECH and out-licenses the platform to create new (and improve existing) orally ingested products.

DehydraTECH is patented for cannabidiol and all other non-psychoactive cannabinoids, as well as for THC (tetrahydrocannabinol) and psychoactive cannabinoids. Additional patents are expected in 2019 as the company continues to investigate how it’s proprietary edible technology can enhance treatment for Parkinsons, Alzheimers, human hormone delivery, erectile dysfunction and more.

CannabisNewsWire (CNW), a multifaceted financial news and publishing company for private and public entities in the cannabis industry, ran an article titled ‘Dramatically Improved Delivery Systems Promise More Effective Cannabis Treatment’ in which LXRP was featured (http://ibn.fm/8u5ep). CNW credited LXRP for leading the way forward for the cannabis industry in discovering new ways to more effectively deliver CBD into the human body.

The article outlined the ways that the industry has struggled to achieve higher rates of absorption. Current cannabis medicines are poorly absorbed by the body, which consequently increases cost and reduces effectiveness. Companies such as LXRP, however, are working to create better delivery systems that make CBD more accessible and improve more lives.

One of the delivery challenges is the amount of CBD waste created, because the human body can only absorb a small amount of the molecules. DehydraTECH is disrupting this cycle by protecting the product during stomach transit, amplifying intestinal absorption by five to ten times over traditional methods and enabling the drug to bypass first-pass liver metabolism. Third-party lab studies have shown a 15- to 20-minute onset of THC effects in humans when using the edible tech.

Products that use the DehydraTECH drug-delivery platform have been shown to deliver CBD faster than those that use medium-chain triglyceride oils. A recent study reported a 319 percent higher CBD blood concentration at 60 minutes when using the DehydraTECH formulation as opposed to coconut oil (http://ibn.fm/tKbuo). Fatty acids used with DehydraTECH have the added benefit of masking the bitter taste of CBD, allowing a better overall experience for the consumer without the need for added sugars or chemicals.

According to the CNW article (http://ibn.fm/2l3ns), the legal changes in Canada and the United States have made it so that suppliers are unable to meet the increase in demand for CBD. DehydraTECH enables the creation and enhancement of products that use smaller amounts of CBD and remain just as effective, thereby reducing production cost and providing a higher quality experience.

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP